Semi-Annual Consolidated Statement Of Cash Flows

Immuno-Biological Laboratories Co., Ltd. - Filing #7581667

Concept As at
2022-09-30
2022-04-01 to
2022-09-30
As at
2022-03-31
As at
2021-09-30
2021-04-01 to
2021-09-30
As at
2021-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-131,581,000 JPY
-195,211,000 JPY
Impairment losses
804,000 JPY
7,041,000 JPY
Interest and dividend income
-630,000 JPY
-65,000 JPY
Interest expenses
536,000 JPY
132,000 JPY
Foreign exchange losses (gains)
-3,191,000 JPY
-816,000 JPY
Share of loss (profit) of entities accounted for using equity method
90,359,000 JPY
57,180,000 JPY
Decrease (increase) in trade receivables
22,460,000 JPY
82,621,000 JPY
Decrease (increase) in inventories
-20,396,000 JPY
-18,918,000 JPY
Increase (decrease) in trade payables
-309,000 JPY
1,217,000 JPY
Other, net
2,613,000 JPY
-20,421,000 JPY
Subtotal
-41,810,000 JPY
-91,115,000 JPY
Interest and dividends received
84,000 JPY
30,000 JPY
Interest paid
-525,000 JPY
-239,000 JPY
Income taxes paid
-8,375,000 JPY
-8,178,000 JPY
Net cash provided by (used in) operating activities
-50,626,000 JPY
-99,503,000 JPY
Cash flows from investing activities
Loan advances
JPY
-10,000,000 JPY
Other, net
50,000 JPY
JPY
Net cash provided by (used in) investing activities
-63,950,000 JPY
-39,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
40,000,000 JPY
Repayments of long-term borrowings
-2,004,000 JPY
-8,000,000 JPY
Net cash provided by (used in) financing activities
2,995,000 JPY
132,000,000 JPY
Other, net
0 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
3,191,000 JPY
816,000 JPY
Net increase (decrease) in cash and cash equivalents
-108,389,000 JPY
-5,687,000 JPY
Cash and cash equivalents
340,795,000 JPY
449,184,000 JPY
546,335,000 JPY
552,022,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.